New combo therapy shows promise in fighting throat cancer, sparing Patients' voices
NCT ID NCT04030455
Summary
This study tested a combination of three drugs—two chemotherapy drugs and an immunotherapy drug—as the main treatment for stage II-III larynx (voice box) cancer. The goal was to see if this approach could effectively control the cancer while allowing patients to keep their larynx, avoiding surgery to remove it. In this small, phase 2 trial, 75% of patients who completed the initial drug cycles had no detectable cancer in follow-up biopsies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.